Cover Image
市場調查報告書

Oramed Pharmaceuticals, Inc.的產品平台分析

Oramed Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253740
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Oramed Pharmaceuticals, Inc.的產品平台分析 Oramed Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年07月08日 內容資訊: 英文 34 Pages
簡介

Oramed Pharmaceuticals, Inc.ha,是開發糖尿病治療以及其他多肽的新口服醫藥品解決方案的製藥公司。

本報告提供Oramed Pharmaceuticals, Inc.的治療藥開發平台的現狀及各開發階段比較分析、藥物標的、作用機制、給藥途徑、各分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

Oramed Pharmaceuticals, Inc.的基本資料

Oramed Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Oramed Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Oramed Pharmaceuticals, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Oramed Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式

Oramed Pharmaceuticals, Inc.:藥物簡介

  • 胰島素注射液
  • (exenatide + 胰島素注射液 (基因重組))
  • exenatide

Oramed Pharmaceuticals, Inc.:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Oramed Pharmaceuticals, Inc.:最近的開發平台趨勢

Oramed Pharmaceuticals, Inc.:暫停中的計劃

Oramed Pharmaceuticals, Inc.:企業發表

Oramed Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07351CDB

Summary

Global Markets Direct's, 'Oramed Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Oramed Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Oramed Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Oramed Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Oramed Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Oramed Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Oramed Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Oramed Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Oramed Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Oramed Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oramed Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Oramed Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Oramed Pharmaceuticals, Inc. Snapshot
    • Oramed Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Oramed Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Oramed Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Oramed Pharmaceuticals, Inc. - Pipeline Products Glance
    • Oramed Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Oramed Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Oramed Pharmaceuticals, Inc. - Drug Profiles
    • insulin human
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (exenatide + insulin human (recombinant))
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • exenatide
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Oramed Pharmaceuticals, Inc. - Pipeline Analysis
    • Oramed Pharmaceuticals, Inc. - Pipeline Products by Target
    • Oramed Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Oramed Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Oramed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Oramed Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Oramed Pharmaceuticals, Inc. - Dormant Projects
  • Oramed Pharmaceuticals, Inc. - Company Statement
  • Oramed Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Oramed Pharmaceuticals, Inc., Key Information
  • Oramed Pharmaceuticals, Inc., Key Facts
  • Oramed Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Oramed Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Oramed Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Oramed Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Oramed Pharmaceuticals, Inc. - Phase II, 2015
  • Oramed Pharmaceuticals, Inc. - Phase I, 2015
  • Oramed Pharmaceuticals, Inc. - Preclinical, 2015
  • Oramed Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Oramed Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Oramed Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Oramed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Oramed Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Oramed Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Oramed Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Oramed Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Oramed Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Oramed Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Oramed Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Oramed Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Oramed Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Oramed Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top